Body statistics turn everyday questions about weight, fitness, and health into measurable facts, and the most recent figures are harder to ignore than ever. In the United States, measured obesity prevalence among adults is 41.9% as of 2023, yet more than 1.4 billion adults worldwide were still insufficiently active back in 2019. Layer in rising chronic disease, the accelerating markets for weight management and digital health, and treatment costs that can exceed thousands per year, and you get a picture where health trends move fast and differently across populations.
Key Takeaways
- 18.5% of adults in the United States report having obesity (BMI ≥ 30.0) in 2023
- 3.3% of U.S. adults (about 8.3 million) reported having chronic kidney disease in 2019–2020
- In 2019, 1.4 billion adults were insufficiently active (WHO)
- The global weight loss market is projected to reach $318.7 billion by 2030 (2023–2030 CAGR implied by projection)
- The global obesity therapeutics market is expected to reach $52.8 billion by 2030
- The global fitness market size was $116.2 billion in 2020 and projected to reach $165.7 billion by 2028
- As of 2023, the U.S. obesity prevalence among adults was 41.9% (measured)
- In 2022, 51.3% of U.S. adults reported having weight-related concerns
- In 2021, 24.0% of U.S. adults used a wearable activity tracker or smartwatch
- In the STEP 1 trial, participants receiving semaglutide 2.4 mg lost a mean of 14.9% body weight at 68 weeks
- In the SURMOUNT-1 trial, tirzepatide achieved mean weight loss of 15.0% to 20.9% at 72 weeks (by dose)
- In the SURMOUNT-3 trial, tirzepatide produced mean weight loss of about 20.9% at 72 weeks
- The incremental annual cost per patient for obesity treatment with GLP-1 receptor agonists versus comparators was estimated at $3,000 in a U.S. claims analysis (peer-reviewed model input)
- NICE appraisal (TA875) assessed semaglutide for managing obesity and reports an incremental cost-effectiveness ratio (ICER) within the decision framework (value stated in the appraisal report)
- OECD estimates obesity-attributable health spending is rising across member countries, with treatment and complications increasing total costs
With obesity affecting 18.5% of U.S. adults, growing markets and trials show promising but costly weight solutions.
Related reading
01 · Category
Health Burden6 stats
01
18.5% of adults in the United States report having obesity (BMI ≥ 30.0) in 2023
02
3.3% of U.S. adults (about 8.3 million) reported having chronic kidney disease in 2019–2020
03
In 2019, 1.4 billion adults were insufficiently active (WHO)
04
WHO estimates 1.9 billion adults worldwide are overweight and 650 million are obese (2022)
05
WHO estimates 462 million adults had diabetes in 2017; the number rose to 537 million by 2021
06
In 2022, U.S. adults with obesity were 42.4% when using measured BMI from NHANES
Interpretation
Health Burden Interpretation
The Health Burden data show that excess weight and related conditions are still escalating, with WHO estimating 1.9 billion adults are overweight and 650 million are obese in 2022, alongside rising diabetes from 462 million in 2017 to 537 million in 2021.
02 · Category
Market Size9 stats
01
The global weight loss market is projected to reach $318.7 billion by 2030 (2023–2030 CAGR implied by projection)
02
The global obesity therapeutics market is expected to reach $52.8 billion by 2030
03
The global fitness market size was $116.2 billion in 2020 and projected to reach $165.7 billion by 2028
04
The global digital health market size was $214.9 billion in 2023
05
The global wearable medical devices market is forecast to reach $25.7 billion by 2029
06
The global sports nutrition market reached $63.3 billion in 2023
07
The U.S. gym membership market generated about $34.1 billion in revenue in 2022 (IBISWorld)
08
The global body composition analysis market size was estimated at $3.8 billion in 2023
09
The global weight management market was valued at $8.8 billion in 2023 and projected to reach $14.6 billion by 2030
Interpretation
Market Size Interpretation
For the Market Size angle, the opportunity in body-focused health is scaling fast, with the global weight loss market projected to grow to $318.7 billion by 2030 alongside rising categories like weight management expected to reach $14.6 billion by 2030.
03 · Category
Adoption And Behavior4 stats
01
As of 2023, the U.S. obesity prevalence among adults was 41.9% (measured)
02
In 2022, 51.3% of U.S. adults reported having weight-related concerns
03
In 2021, 24.0% of U.S. adults used a wearable activity tracker or smartwatch
04
In 2023, global consumers aged 16+ used at least one health app monthly at a rate of 23% (consumer health app adoption survey by data.ai)
Interpretation
Adoption And Behavior Interpretation
Even as 41.9% of U.S. adults are obese and 51.3% report weight-related concerns, only 24.0% use a wearable activity tracker or smartwatch and 23% of global consumers aged 16+ use a health app monthly, showing a clear adoption gap in the Adoption And Behavior category.
04 · Category
Performance Metrics6 stats
01
In the STEP 1 trial, participants receiving semaglutide 2.4 mg lost a mean of 14.9% body weight at 68 weeks
02
In the SURMOUNT-1 trial, tirzepatide achieved mean weight loss of 15.0% to 20.9% at 72 weeks (by dose)
03
In the SURMOUNT-3 trial, tirzepatide produced mean weight loss of about 20.9% at 72 weeks
04
In a meta-analysis, mobile health interventions increased physical activity by an average of 1.1 days per week
05
In a Cochrane review, lifestyle interventions produced an average additional 3.04 kg weight loss compared with control at 12 months
06
In a randomized trial, a wearable-assisted weight loss program resulted in 3.3% greater weight loss than a control at 12 months
Interpretation
Performance Metrics Interpretation
Across these performance metrics, weight-loss treatments and supportive interventions show clear impact with semaglutide 2.4 mg producing a mean 14.9% loss by 68 weeks and tirzepatide reaching about 20.9% by 72 weeks, while added lifestyle and technology support also improves outcomes such as an extra 3.04 kg at 12 months and 1.1 more days of physical activity per week.
More related reading
05 · Category
Cost Analysis6 stats
01
The incremental annual cost per patient for obesity treatment with GLP-1 receptor agonists versus comparators was estimated at $3,000in a U.S. claims analysis (peer-reviewed model input)
02
NICE appraisal (TA875) assessed semaglutide for managing obesity and reports an incremental cost-effectiveness ratio (ICER) within the decision framework (value stated in the appraisal report)
03
OECD estimates obesity-attributable health spending is rising across member countries, with treatment and complications increasing total costs
04
A 2023 systematic review reported that commercial weight management programs cost participants from tens to hundreds of dollars per month, with wide variance by program model
05
In a real-world study of anti-obesity medication costs, annual medication costs for GLP-1 therapies can exceed $6,000per patient depending on dose and persistence (claims-based analysis)
06
In the U.S., the average retail price of a 28-day supply of GLP-1 obesity medications can be several hundred to over $1,000depending on drug and dosage (survey of published WAC prices)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, obesity treatment costs are substantial and growing, with annual per patient costs for GLP-1 therapies reaching about $3,000 in claims models and real-world medication spending often exceeding $6,000 depending on dose and persistence, while participant program fees range from tens to hundreds of dollars per month and total health expenditures rise across OECD countries due to both treatment and complications.
06 · Category
Health Comorbidities1 stats
01
4.0% of U.S. adults reported having diagnosed diabetes in 2022 — CDC NHIS estimates quantify diabetes prevalence.
Interpretation
Health Comorbidities Interpretation
In the Health Comorbidities category, 4.0% of U.S. adults reported having diagnosed diabetes in 2022, underscoring how a notable share of the population lives with a chronic condition that can complicate overall health.
07 · Category
Industry Trends1 stats
01
3.5% of U.S. total health expenditures were linked to obesity in 2019 — OECD Health Statistics-based analysis (as compiled in OECD report) quantified obesity-attributable spending share.
Interpretation
Industry Trends Interpretation
In industry trends for Body, obesity accounted for 3.5% of total US health expenditures in 2019, underscoring how a single health condition can represent a meaningful slice of spending and shape market priorities.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Sutherland. (2026, February 13). Body Statistics. Gitnux. https://gitnux.org/body-statistics
MLA
David Sutherland. "Body Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/body-statistics.
Chicago
David Sutherland. 2026. "Body Statistics." Gitnux. https://gitnux.org/body-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+14 additional datasets cited (not shown individually)